Nov 5
Current report
8-K
Events of Nov 4
Director or officer change, or executive pay
AI summary on its way
GEHC · GE HealthCare Technologies Inc.
$83.75
-2.06 (-2.40%)
At close · Nov 5
Return incl. dividend (before tax)
Market Cap
$38.80B
Shares
452.14M
Volume · Nov 5
6.28M
Avg daily vol (3M)
3.59M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$83.75
Open$86.25
Day$82.72–87.24
52W close$59.49–88.16
Avg vol 30d4.2M
Short int19.4M · 4.3% of shares · 5.1d
Short vol53%
Last earningsOct 28, 2026
DataDec 2022–Nov 2026
Filing10-Q · Oct 28
Up next
Jan 27, 2027
Est · unconfirmed
· in 12 wks
Latest documents
2026
Oct 28
Earnings call
Q3 2026 earnings call
GE HealthCare reported third-quarter revenue of $5.5 billion, up 6.2% organically, adjusted EPS of $1.34, up 25.1%, and raised full-year 2026 guidance to approximately 4% organic revenue growth and $4.95 to $5.05 adjusted EPS.
Oct 28
Quarterly report
10-Q
FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3
GE HealthCare Technologies Inc. reported total revenues of $5,513 million, up 7.2%, and operating income of $805 million for the three months ended September 30, 2026; nine-month revenues were $15,939 million, up 6.8%, and operating income was $2,058 million.
Revenue $5.51B
▲ 7.2%
Net income $615M
▲ 37.9%
Diluted EPS $1.36
▲ 38.8%
Oct 28
Current report
8-K
Events of Oct 22
Financial results, Director or officer change, or executive pay
GE HealthCare Technologies Inc. reported third-quarter 2026 revenue growth of 7.2%, raised full-year 2026 Adjusted EPS guidance to $4.95 - $5.05, and announced Jeannette Bankes’ November 15, 2026 departure and Neal Sandy’s November 16, 2026 start leading Patient Care Solutions.
Sep 22
Current report
8-K
Director or officer change, or executive pay, Regulation FD disclosure
GE HealthCare Technologies Inc. appointed Pascal Desroches, AT&T’s CFO, to its Board of Directors effective January 4, 2027, and to its Audit Committee and Talent, Culture, and Compensation Committee. Desroches plans to retire from AT&T on December 31, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$21.64B
Trailing 12 months
Net income (TTM)
$2.15B
Trailing 12 months
Revenue growth YoY
+7.2%
Year over year
Operating margin
13.3%
Trailing 12 months
P / E (TTM)
18.1
Trailing earnings · reciprocal yield 5.5%
FCF yield
4.9%
TTM · current market cap
Return on invested capital
12.3%
Trailing 12 months
Net cash
−$7.15B
Latest balance sheet
Dividend yield
0.2%
Trailing 12 months
Shares change YoY
-0.9%
Year over year · fewer shares
Price change (1Y)
+15.5%
Trailing year
Short interest
4.3%
Latest settlement · 5.1 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 28.2 · fear
Equity put/call 0.44
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
+21%
above
RSI (14)
77
overbought
MACD trend
Positive
52-week position
85%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+30%
trailing
6-month return
+38%
trailing
YTD return
+2%
this year
Relative strength
+39%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $69 › 200d $70 — 200d above 50d
Institutional flow
Accumulating
651 of 1,241 funds reported for Sep 30 · net +3.2M sh shares · +54 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.29% of shares out · ▲ +4.6% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1,241 holders — mid 3-yr range
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
+5%
Y/Y
Gross margin
40%
contracting
EPS growth
+5%
Y/Y
Valuation
P/E 18.1
below peers
Buyback
$500.0M
remaining
Balance sheet
$5.5B
net debt
Quant / Vol
risk profile
Volatility
36%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
3.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jul 29, 2026
full-year 2026
Organic sales growth
Non-GAAP
3% – 4%
Adjusted EBIT margin expansion
Non-GAAP
10% – 40%
Adjusted EBIT margin
Non-GAAP
Maintained
15.4% – 15.7%
Apr 29, 2026
15.4% – 15.7%
changed to
Jul 29, 2026
15.4% – 15.7%
Free cash flow
Maintained
$1.6B
Apr 29, 2026
$1.6B
changed to
Jul 29, 2026
$1.6B
full year 2026
Organic sales growth
Non-GAAP
3% – 4%
Previous outlook
earlier release
· from the Earnings Call filed Apr 29, 2026
Still-open targets the latest release did not restate under the same label.
Organic sales growth
· this year
3% – 4%
Prior guidance
period ended
· from the Earnings Call filed Jul 29, 2026
Organic revenue growth
· third quarter
3% – 4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
+21%
Bullish
RSI (14)
77
Bearish
MACD trend
Positive
Bullish
52-week position
85%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $69 › 200d $70 — 200d above 50d
Institutional flow
Accumulating
651 of 1,241 funds reported for Sep 30 · net +3.2M sh shares · +54 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.29% of shares out · ▲ +4.6% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1,241 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $59
Now $84 · 85%
Range high $88
vs 200-day avg +20%
vs 50-day avg +21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GEHC
this stock
GE HealthCare Technologies Inc.
|
$38.80B | +2.1% | +4.8% | 18.1 | 4.3% |
|
ABT
Abbott Laboratories
|
$196.75B | -9.3% | +5.7% | 42.4 | 1.0% |
|
MDT
Medtronic plc
|
$134.26B | +9.1% | +8.4% | 25.9 | 10.9% |
|
SYK
Stryker Corp
|
$127.55B | -4.7% | +11.2% | 35.7 | 1.5% |
|
BSX
Boston Scientific Corp
|
$64.70B | -53.2% | +12.5% | 18.9 | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GEHC | +9.6% | +30.4% | +37.8% | +9.4% | +2.1% |
| SPY | -4.7% | -5.3% | -0.8% | -3.0% | +7.5% |
| vs SPY | +14.3% | +35.7% | +38.7% | +12.4% | -5.4% |
Capital returns
Latest dividend
$0.04
/ share · ex Oct 23, 2026
Paid (TTM)
$0.145
/ share · 4 payouts
Dividend yield (TTM, derived)
0.17%
Buyback program
· as of Sep 30, 2026
Authorized
$1.00B
Spent (derived)
$500.00M
Remaining
$500.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1932393
CUSIP
36266G107
13F (30d)
650 filings
596 filers
Visit website
Investor relations